← Leaderboards
John M Rabkin
Oregon Health And Science University
$344,822
Attributed
$344,822
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$344,822 · 2
By mechanism
M01$344,822 · 2
Top collaborators
No co-investigators on record.
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Daniel N Streblow$31,877,942
- Dennis Royal Trune$12,148,826
- Hugo R Rosen$16,057,795
- Markus Grompe$34,224,681
- Michael G Gravett$2,126,717
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationClinical ResearchHuman SubjectHuman Therapy EvaluationCytomegalovirusDrug Administration Rate /DurationDrug Adverse EffectDrug InteractionsFk506GanciclovirGastrointestinal Drug AbsorptionKidney DisorderLiver TransplantationMicroorganism Disease ChemotherapyMycophenolate MofetilOral AdministrationPharmacokineticsPrednisoneAntiviral AgentsTransplant RejectionChemopreventionCombination ChemotherapyComorbidity
Grant awards (6)
PHARMACOKINETICS OF GANCICLOVIR IN FOUR DIFFERENT DRUG REGIMENS$172,411
M01 · FY2001 · RR
CellCept in post-liver transplant patients with renal impairment on FK506$172,411
M01 · FY2001 · RR
PHARMACOKINETICS OF GANCICLOVIR IN FOUR DIFFERENT DRUG REGIMENS$0
M01 · FY2001 · RR
CellCept in post-liver transplant patients with renal impairment on FK506$0
M01 · FY2001 · RR
PHARMACOKINETICS OF GANCICLOVIR IN FOUR DIFFERENT DRUG REGIMENS$0
M01 · FY2000 · RR
CellCept in post-liver transplant patients with renal impairment on FK506$0
M01 · FY2000 · RR